Results 61 to 70 of about 5,855,418 (301)
Ovarian response and reproductive outcome during ovarian stimulation.
, 2013 Ovarian response and reproductive outcome during ovarian stimulation.
Tito Silvio Patrelli (308275) +6 more
core +1 more source
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Molecular Oncology, EarlyView.Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder +10 more
wiley +1 more source
Frontiers in Endocrinology, 2019 Research Question: What is the effect of gonadotropin-releasing hormone (GnRH)-agonist treatment on serum anti-Müllerian hormone (AMH)?Design: This prospective cohort study conducted in a tertiary university hospital comprised patients (n = 52) who self ...
Panagiotis Drakopoulos +13 more
doaj +1 more source
Frontiers in Endocrinology, 2023 BackgroundThe basal follicle stimulating hormone (FSH)/luteinizing hormone (LH) ratio is a useful predictor of ovarian response. In this study, we investigated whether the FSH/LH ratios during the entire controlled ovarian stimulation (COS) can be used ...
Shen Zhao +8 more
doaj +1 more source
Ovarian Response to hCG in the Postweaning Sow.
Journal of Veterinary Medical Science, 1993 Five non-cyclic postweaning sows were given intramuscularly 1,000 IU of hCG on day 2 (4 sows) and day 36 (1 sow) after weaning. Single or multiple follicular cysts were developed in ovaries in all cases. Plasma E2 fluctuated at low levels in 4 of 5 sows resulting in silent heat.
OGASA, Akira +2 more
openaire +3 more sources
Clinical resistance to platinum chemotherapy in ovarian cancer [PDF]
, 2009 Platinum drugs are the most active agents in ovarian cancer. Their cytotoxicty results from DNA crosslinking. High tumour response rates are seen, but 80 % of patients relapse. Major mechanisms of platinum resistance in patients remain to be established.
Newton, C., Newton, C
core
Molecular Oncology, EarlyView.The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
Investigating the potential for expediting diagnosis of ovarian cancer via prompt symptom recognition & "targeted screening" [PDF]
, 2009 PhDThis thesis explores the potential for using symptoms as a tool to bring forward the diagnosis of ovarian cancer. Current evidence supports the existence of prediagnostic symptoms, however symptom lead time has yet to be adequately quantified ...
Lim, Anita Wey Wey
core +2 more sources
Journal of Human Reproductive Sciences, 2013 Objective: The objective of this study was to test the hypothesis that AMH and antral follicle count (AFC) are good predictors of ovarian response to controlled ovarian stimulation and to compare them.
Y Himabindu +5 more
doaj +1 more source
Molecular Oncology, EarlyView.Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park +6 more
wiley +1 more source